Costa Rica, the land of pura vida, stunning national parks and biodiversity, has transformed itself from an agricultural-focused exporter into a high-tech manufacturing hub. “Medical devices are now our biggest export,” said Keiner Morales, chief technology officer at Lantern Med Digital. The country has transformed considerably since the 1980s. “Back then, we were a coffee-and-banana…
Norstella launches Atlas, a biopharma agentic platform that can ‘train you’
Enterprise software in drug development tends to arrive slowly. Laboratory information management systems, quality platforms and the enterprise resource planning software they connect to typically take months to deploy. In Panorama Consulting Group’s 2026 ERP report, based on 170 organizations across industries surveyed between January 2025 and January 2026, the median project ran nine months,…
How a Duke-led HPC method brought cell-scale cancer simulation to a single cloud node
Even on the largest supercomputers, simulations that explicitly resolve every blood cell can only cover a small volume. On Summit, Oak Ridge National Labs’ supercomputer, cell-resolved simulations topped out at roughly a three-millimeter cube. Exascale machines like Aurora and Frontier have pushed that to about a one-centimeter cube with several billion cells, up from around 500 million, said Amanda Randles of Duke…
As AI floods drug discovery with designs, Twist uses DNA chips to tackle the wet-lab bottleneck
Whatever your take on the current AI wave, it is clear that the prospect of creating software has been transformed. “The most impressive edge of it is probably using [genAI models] to help speed code development. And that’s kind of working,” said the computer scientist Jaron Lanier recently. Frontier AI labs are now pushing for…
Recursion says its Norstella-backed real-time simulation can expand trial eligibility by up to 40%
Clinical trials are notoriously difficult to predict, and they have grown more so as protocols pile on endpoints, procedures and eligibility rules. As that complexity climbs, so do the odds of studies needing mid-course changes. The share of Phase 1 through 4 protocols requiring at least one amendment hit 76%, up from 57% in 2015,…
NIH employees warn of ‘institutionalized destruction’ one year after Bethesda Declaration
One year after nearly 500 National Institutes of Health (NIH) employees signed a letter warning that political interference was threatening the agency’s mission, the authors of a new report say the situation has only gotten worse. “The chaos of 2025 has been replaced with coordinated, systematic, institutionalized destruction in 2026,” the Bethesda Declaration: One Year…
Cradle’s CEO on the AI agent boom and the reality of experimental feedback in life sciences
Within roughly 18 months, Google DeepMind, Microsoft, Amazon, NVIDIA, OpenAI and Anthropic have all launched or upgraded products aimed at scientific research, many of them built around AI agents that promise to compress the earliest, most expensive stages of discovery. That push builds on the explosive growth of AI coding tools. Even as many frontier…
Inside BD’s plan to forecast hospital drug demand with AI while keeping models within bounds
When Becton, Dickinson and Company launched its Incada Connected Care Platform in October 2025 with the next-generation Pyxis Pro dispensing system, it framed the move as a way to turn data from nearly 3 million smart connected BD devices into actionable insights on medication inventory, waste and clinician workflows. Omar Ahmed, who joined BD as…
Mayo Clinic backs ViewsML in $4.9M round to advance virtual biomarker staining
ViewsML, the Vancouver-based company developing what it calls the world’s first virtual biomarker library, closed an oversubscribed $4.9 million seed round earlier this year. Wittington Ventures, the Toronto venture arm of the Weston family holding company, led the round. New investors Mayo Clinic and Continuum Health Ventures participated alongside repeat backers including Debiopharm. In an…
How a plant virus could keep astronauts medicated on a trip to Mars
A comprehensive analysis of the expected shelf-lives of the entire 2023 ISS formulary found that 54 of 91 medications have a terrestrial shelf-life of 36 months or less, which could be accelerated by space radiation. As NASA aims for Mars missions, which take about 200 days, resupply becomes unrealistic. Now, researchers at the University of…
Countable Labs’ CTO Christina Fan on reimagining PCR, one molecule at a time
Countable Labs, a Palo Alto company built around direct single-molecule counting, has raised $26 million in an oversubscribed round to push its Countable PCR platform toward the clinic and global commercialization. Countable Labs’ twist on standard PCR doesn’t rely on microfluidics, physically isolating single DNA or RNA targets into over 30 million picoliter-sized compartments within…
Noetik’s TARIO-2: A ‘world model’ that reads a tumor from a single slide
Many patients who receive cancer immunotherapy do not respond to it, and oncologists still have few dependable ways to know in advance who will. By one estimate, only about 13% of all U.S. cancer patients stand to benefit from checkpoint inhibitors, and drugmakers are increasingly betting on AI to improve those odds. Noetik, a South…
Six months in, Lilly says its supercomputer is starting to change the work with ‘near-infinite’ AI tokens
When Eli Lilly and NVIDIA unveiled what they called the pharmaceutical industry’s most powerful supercomputer in October 2025, the story was mostly about scale. The Lilly-owned system, now branded LillyPod, brings more than 1,000 Blackwell Ultra GPUs into a DGX SuperPOD designed to support drug discovery, manufacturing, medical imaging and enterprise AI agents. At January’s…
Boltz built its drug-discovery API ‘for agents as much as for people’
Since AlphaFold 2 cracked protein-structure prediction in 2020 and 2021, a growing ecosystem of biomolecular models has followed, including Boltz, Chai, OpenFold and Protenix. Yet commercial access remains uneven. AlphaFold 3, launched in 2024, broadened the field from protein folding to biomolecular interactions, while its public server remains off-limits for commercial use. DeepMind’s commercial engine…
NVIDIA Announces BioNeMo Agent Toolkit with traction from nearly 50 partners, including Lilly, Thermo Fisher and Dassault
NVIDIA has unveiled the BioNeMo Agent Toolkit, an open, harness-agnostic platform that gives AI agents or software platforms the building blocks to specialize for science. Debuting with adoption from nearly 50 partners, including Eli Lilly, Thermo Fisher Scientific and Dassault Systèmes, the toolkit packages NVIDIA’s life-sciences software, models for tasks such as protein-structure prediction, molecular…
MilliporeSigma’s CTO on AI retrosynthesis, the Merck KGaA–Siemens deal and the chemistry that runs the autonomous lab
Over the past decade and a half, the Darmstadt-based Merck KGaA has assembled a supplier that touches nearly every bench in the lab. It bought Millipore in 2010, with the membrane filters and Milli-Q water systems that had been lab staples since the 1950s, and added Sigma-Aldrich and its ubiquitous reagents catalog in 2015 for…
Medable’s Digital Data Flow Agent focuses on protocol translation as the agentic race accelerates
In January 2024, Medable, the decentralized clinical-trial company headquartered in Palo Alto, used AI to translate a study protocol directly into a configured eCOA mobile app, complete with questionnaires, workflows and translation into roughly 25 languages. The company said then the feature could halve eCOA deployment timelines, which had typically run 12 to 16 weeks.…
AI image firm Midjourney spins up health division, unveils ‘Ultrasonic CT’
A blog post from the AI image company announced the launch of a whole-body ultrasound scanner users would step into through a pool of water. “We’re building a bold new kind of machine to reimagine the foundations of healthcare and our relationships to our bodies,” the company noted. The “Ultrasonic CT” will be featured in…
Q&A: Owkin’s five-year Sanofi deal bets on ‘purpose-built’ AI agents
Over the past two years, software engineering has handed a growing share of its routine work to AI agents. At one end of the spectrum, companies ranging from Google to Anthropic use AI to write the bulk of their code. At the other, there are reports of the bills coming due for heavy users at…
Genetically modified hookworms could produce and deliver therapeutics within a host
Researchers at Washington University have genetically engineered hookworms to produce and secrete a human antibody, creating a “living pharmaceutical biofactory,” according to the study published in Nature Communications. To survive within the human gut, hookworms secrete over 800 molecules to modulate inflammation and maintain homeostasis. “We thought: what if we make it secrete one more…
Leica, Indica Labs and Lunit team up as AI biomarker scoring moves toward clinical scale
Digital pathology matured quickly during the pandemic, when remote work needs and temporary FDA enforcement discretion lowered the perceived barriers to whole-slide imaging. Capital followed. Roche’s May agreement to acquire PathAI for up to $1.05 billion, pending closing, is only the most recent sign of how much money is chasing the field. The most valuable…
Beyond the sequence: how Ötzi the Iceman exposed the blind spots of pure metagenomics
A team of researchers recently uncovered living microorganisms on the remains of the 5,300-year-old Iceman, revealing a methodological gap in modern genomics. In a study published in Microbiome, the team showed that while DNA analysis can map the presence of ancient genetic material, traditional petri dish cultivation remains necessary to determine if those microorganisms are…
Flatworms sacrifice healthy cells to destroy the root cause of mutations in explosive immune response
Stanford scientists have discovered a new kind of cell death in flatworm immune cells. Called ruptosis, the mechanism results in the cell exploding and taking out approximately 70 cells surrounding it. The flatworms, Schmidtea mediterranea, evolved to sacrifice healthy cells through this process in order to ensure the elimination of biological threats. Unlike vertebrate immune…
OpenAI research and product leads detail GPT-Rosalind capabilities and benchmarks
Solving humanity’s biggest problems has been OpenAI’s stated reason for pursuing artificial general intelligence since its 2015 founding, and over time, life science challenges have crystallized as core parts of its vision. In February 2025, CEO Sam Altman wrote that “we can now imagine a world where we cure all diseases,” and by that September…
Sanofi deepens its Owkin bet with a five-year deal to build bespoke drug-development agents
Agentic AI company Owkin and Sanofi have extended their collaboration with a five-year license for K Pro, Owkin’s AI scientist, under which Owkin will lead the end-to-end development of novel, purpose-built biopharma agents for Sanofi. Owkin pitches K Pro as a system that reasons over biological data and orchestrates AI agents to run research and…
























